The eight words of "repeated defeats, repeated defeats and repeated battles" may be the best interpretation of the various performances of Simcere Pharmaceutical in recent years

The eight words of "repeated defeats, repeated defeats and repeated battles" may be the best interpretation
of the various performances of Simcere Pharmaceutical in recent years.

The eight words of "repeated defeats, repeated defeats and repeated battles" may be the best interpretation
of the various performances of Simcere Pharmaceutical in recent years.

From the impact of Simcere Pharmaceuticals on Hong Kong stocks in 2020 to the abuse of the dominant market position in the sales of batraxase APIs in 2021 and a fine of 100.

From the impact of Simcere Pharmaceuticals on Hong Kong stocks in 2020 to the abuse of the dominant market position in the sales of batraxase APIs in 2021 and a fine of 100.

However, recently, in the seventh batch of collection, Simcere Pharmaceutical "took the lead", its lenvatinib fell by 97%, and won the bid at the lowest price of 3.

However, recently, in the seventh batch of collection, Simcere Pharmaceutical "took the lead", its lenvatinib fell by 97%, and won the bid at the lowest price of 3.

This time, why does Simcere Pharmaceutical dare to use the price of an ice cream to sweep the liver cancer targeted drugs?

This time, why does Simcere Pharmaceutical dare to use the price of an ice cream to sweep the liver cancer targeted drugs?

Rooted in generic drugs, onslaught on innovative drugs

Rooted in generic drugs, onslaught on innovative drugs to take root in generic drugs, onslaught on innovative drugs to take root in generic drugs, onslaught on innovative drugs

Product research and development is the foundation of innovative pharmaceutical companies, and Simcere Pharmaceutical is no exception
.

Product research and development is the foundation of innovative pharmaceutical companies, and Simcere Pharmaceutical is no exception
.

Simcere Pharma focuses on the three major areas of oncology, nervous system and autoimmunity, and actively and proactively lays out the disease areas
with significant clinical needs in the future.

Simcere Pharma focuses on the three major areas of oncology, nervous system and autoimmunity, and actively and proactively lays out the disease areas
with significant clinical needs in the future.

In 2021, Simcere Pharmaceuticals invested 1.

In 2021, Simcere Pharmaceuticals invested 1.

And this statement is also reflected in the income data:

And this statement is also reflected in the income data:

In 2021, Simcere Pharmaceutical's innovative drug revenue was 3.

In 2021, Simcere Pharmaceutical's innovative drug revenue was 3.
12 billion yuan, an increase of 53.
8% over the same period last year, which can be described as the "Simcere speed"
that shows its innovation strength to the outside world.

Take the self-developed innovative drug Xianbixin as an example: the drug's strong sales growth in the past year led to a 119.
3% increase in the revenue of the nervous system business to RMB1.
543 billion
.

Take the self-developed innovative drug Xianbixin as an example: the drug's strong sales growth in the past year led to a 119.
3% increase in the revenue of the nervous system business to RMB1.
543 billion
.

In particular, the collaborative innovative drug Nvida was approved for listing in November 2021, which is the world's first and currently the only subcutaneous PD-L1 antibody drug approved for marketing, bringing new business growth points
.

In particular, the collaborative innovative drug Nvida was approved for listing in November 2021, which is the world's first and currently the only subcutaneous PD-L1 antibody drug approved for marketing, bringing new business growth points
.

Other clinical advances: the progress of the third phase of the key clinical trial of the first benebxin sublingual tablets exceeded expectations; The final sprint stage of the clinical declaration of oral 3CL anti-new crown small molecule drugs ranks at the forefront of the research and development progress of similar products in China.
.
.
.
.
.

Other clinical advances: the progress of the third phase of the key clinical trial of the first benebxin sublingual tablets exceeded expectations; The final sprint stage of the clinical declaration of oral 3CL anti-new crown small molecule drugs ranks at the forefront of the research and development progress of similar products in China.
.
.
.
.
.

According to the official website data, Simcere Pharmaceutical and other companies jointly have nearly 60 innovative drug research and development pipelines, and have carried out 19 registered clinical studies
on 16 potential innovative drugs.

According to the official website data, Simcere Pharmaceutical and other companies jointly have nearly 60 innovative drug research and development pipelines, and have carried out 19 registered clinical studies
on 16 potential innovative drugs.

Image source: Simcere Pharmaceuticals official website

Image source: Simcere Pharmaceuticals official website

Just last week, Simcere Pharmaceuticals' world-first new bone marrow protection drug, Traxilil (trade name: Cocera), was conditionally approved for marketing
in China.

Just last week, Simcere Pharmaceuticals' world-first new bone marrow protection drug, Traxilil (trade name: Cocera), was conditionally approved for marketing
in China.

Indications are prophylactic administration of generalized small cell lung cancer patients who have not previously received systemic chemotherapy prior to treatment with platinum-containing drugs combined with etoposide regimens to reduce the incidence
of chemotherapy-induced bone marrow suppression.

Indications are prophylactic administration of generalized small cell lung cancer patients who have not previously received systemic chemotherapy prior to treatment with platinum-containing drugs combined with etoposide regimens to reduce the incidence
of chemotherapy-induced bone marrow suppression.

The drug will fill an important clinical gap
in the treatment of small cell lung cancer.

The drug will fill an important clinical gap
in the treatment of small cell lung cancer.

Dr.
Renhong Tang, Executive Director of Simcere Pharmaceuticals, said that it will accelerate the development of other indications of Trasilide, which shows Simcere Pharmaceutical's ambition
in the field of innovative drugs.

Dr.
Renhong Tang, Executive Director of Simcere Pharmaceuticals, said that it will accelerate the development of other indications of Trasilide, which shows Simcere Pharmaceutical's ambition
in the field of innovative drugs.

Strengthen independent research and development, expand cooperative development

Enhance independent research and development, expand cooperative development and enhance independent research and development, expand cooperative development and enhance independent research and development, and expand cooperative development

In addition to the above independent research and development of innovative drugs, Simcere Pharmaceutical has also accelerated the pace of
cooperative research and development.

In addition to the above independent research and development of innovative drugs, Simcere Pharmaceutical has also accelerated the pace of
cooperative research and development.

In order to consolidate the achievements of existing innovative drugs and quickly seize the innovative drug market, Simcere Pharmaceutical has increased its horsepower in the past two years, holding hands with domestic and foreign innovative drug companies (institutions) to take the "express":

In order to consolidate the achievements of existing innovative drugs and quickly seize the innovative drug market, Simcere Pharmaceutical has increased its horsepower in the past two years, holding hands with domestic and foreign innovative drug companies (institutions) to take the "express":

We have collaborated 5 times to jointly develop innovative drugs and obtain commercialization interests
.

We have collaborated 5 times to jointly develop innovative drugs and obtain commercialization interests
.

PI3K/mTOR pathway inhibitor: Paxalisib

PI3K/mTOR pathway inhibitor: PaxalisibPI3K/mTOR pathway inhibitor: Paxalisib

In March 2021, Simcere Pharmaceuticals and Kazia Therapeutics, an Australian oncology drug discovery company, announced the signing of an exclusive licensing agreement
for the anti-tumor drug Paxalisib in Greater China.

In March 2021, Simcere Pharmaceuticals and Kazia Therapeutics, an Australian oncology drug discovery company, announced the signing of an exclusive licensing agreement
for the anti-tumor drug Paxalisib in Greater China.

According to the data, more than 85% of glioblastoma cases have PI3K pathway abnormalities, and Paxalisib is a brain-penetrating PI3K/mTOR pathway inhibitor, and is currently conducting global Phase II/III.
GBM AGILE glioblastoma platform clinical trials
.

According to the data, more than 85% of glioblastoma cases have PI3K pathway abnormalities, and Paxalisib is a brain-penetrating PI3K/mTOR pathway inhibitor, and is currently conducting global Phase II/III.
GBM AGILE glioblastoma platform clinical trials
.

2 Alzheimer's disease (AD) drugs

2 Alzheimer's disease (AD) drugs and 2 Alzheimer's disease (AD) drugs

In June 2021, Simcere Pharmaceuticals and Vivoryon Therapeutics N.
V.
, a biotechnology company focused on developing innovative drugs for small molecules, established a strategic regional licensing partnership to develop and commercialize Alzheimer's disease (AD) therapies targeting neurotoxic amyloid N3pE (pGlu-Aβ) in Greater China
.

In June 2021, Simcere Pharmaceuticals and Vivoryon Therapeutics N.
V.
, a biotechnology company focused on developing innovative drugs for small molecules, established a strategic regional licensing partnership to develop and commercialize Alzheimer's disease (AD) therapies targeting neurotoxic amyloid N3pE (pGlu-Aβ) in Greater China
.

Under the agreement, Simcere will be licensed to develop and commercialize two AD drugs developed by Vivoryon in Greater China, namely Varoglutamstat (PQ912), an oral small molecule glutatidyl peptide cyclotransferase (QPCT) inhibitor targeting N3pE, in Phase II.
b, and PBD-C06
, a monoclonal N3pE antibody in preclinical research.

Under the agreement, Simcere will be licensed to develop and commercialize two AD drugs developed by Vivoryon in Greater China, namely Varoglutamstat (PQ912), an oral small molecule glutatidyl peptide cyclotransferase (QPCT) inhibitor targeting N3pE, in Phase II.
b, and PBD-C06
, a monoclonal N3pE antibody in preclinical research.

This became a sign
of Simcere Pharmaceuticals' entry into the AD drug.

This became a sign
of Simcere Pharmaceuticals' entry into the AD drug.

3CL target anti-novel coronavirus drugs

3CL target anti-novel coronavirus drug 3CL target anti-novel coronavirus drug

In November 2021, Simcere Pharmaceuticals announced that it has reached a project cooperation
with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences (Shanghai Institute of Materia Medica) and others on the development of new drugs against novel coronavirus (SARS-CoV-2).

In November 2021, Simcere Pharmaceuticals announced that it has reached a project cooperation
with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences (Shanghai Institute of Materia Medica) and others on the development of new drugs against novel coronavirus (SARS-CoV-2).

The candidate molecules have the potential to become a new generation of oral COVID-19 drugs, and have a strong inhibitory effect
on a variety of COVID-19 variants, including Delta strains.

The candidate molecules have the potential to become a new generation of oral COVID-19 drugs, and have a strong inhibitory effect
on a variety of COVID-19 variants, including Delta strains.

Under the arrangement, Simcere Pharmaceuticals will be granted exclusive rights
to develop, manufacture and commercialize the SIM0417 series of anti-coronavirus drug candidates worldwide.

Under the arrangement, Simcere Pharmaceuticals will be granted exclusive rights
to develop, manufacture and commercialize the SIM0417 series of anti-coronavirus drug candidates worldwide.

Innovative drug for acute ischemic stroke

Innovative drug for acute ischemic strokeInnovative drug for acute ischemic stroke

In December 2021, Simcere Pharmaceuticals and Avilex Pharma, a biotechnology company for the development of new drugs for the central nervous system in the clinical stage of Denmark, entered into a regional strategic licensing cooperation to introduce AVLX-144, an innovative stroke drug targeting PSD-95, in the Greater China region (Chinese mainland, Hong Kong, Macau and Taiwan) for the development, production and commercialization of
all indications including acute ischemic stroke (AIS).

In December 2021, Simcere Pharmaceuticals and Avilex Pharma, a biotechnology company for the development of new drugs for the central nervous system in the clinical stage of Denmark, entered into a regional strategic licensing cooperation to introduce AVLX-144, an innovative stroke drug targeting PSD-95, in the Greater China region (Chinese mainland, Hong Kong, Macau and Taiwan) for the development, production and commercialization of
all indications including acute ischemic stroke (AIS).

AVLX-144 is a dimer peptide candidate for postsynaptic densin 95 (PSD-95, an intracellular scaffold protein) that can be used to treat acute ischemic stroke (AIS) and acute subarachnoid hemorrhage (SAH) with the aim of improving prognosis
in stroke patients.

AVLX-144 is a dimer peptide candidate for postsynaptic densin 95 (PSD-95, an intracellular scaffold protein) that can be used to treat acute ischemic stroke (AIS) and acute subarachnoid hemorrhage (SAH) with the aim of improving prognosis
in stroke patients.

JAK1 inhibitors

JAK1 inhibitorsJAK1 inhibitors

In March 2022, Simcere Pharmaceutical and Lingke Pharmaceutical (Hangzhou) Co.
, Ltd.
(hereinafter referred to as "Lingke Pharmaceutical") announced a strategic cooperation on
the commercialization of the selective JAK1 inhibitor LNK01001.

In March 2022, Simcere Pharmaceutical and Lingke Pharmaceutical (Hangzhou) Co.
, Ltd.
(hereinafter referred to as "Lingke Pharmaceutical") announced a strategic cooperation on
the commercialization of the selective JAK1 inhibitor LNK01001.

It is reported that JAK1 is an important subtype of intracellular non-receptor tyrosine kinase family JAKs, which is closely related
to the pathogenesis of a variety of autoimmune diseases.
The highly selective JAK1 inhibitors that have been listed abroad have shown significant advantages
in 6 clinical studies of head-to-head treatment of rheumatoid arthritis with methotrexate or biologics.

It is reported that JAK1 is an important subtype of intracellular non-receptor tyrosine kinase family JAKs, which is closely related
to the pathogenesis of a variety of autoimmune diseases.
The highly selective JAK1 inhibitors that have been listed abroad have shown significant advantages
in 6 clinical studies of head-to-head treatment of rheumatoid arthritis with methotrexate or biologics.

As can be seen above, from the popular 3CL target anti-new coronavirus drugs to AD drugs, it is shown that Simcere Pharmaceutical has gradually explored a set of suitable commercialization paths from independent research and development and cooperative research and development, and further promoted the pace
of drug research and development and commercialization of Simcere Pharmaceuticals.

As can be seen above, from the popular 3CL target anti-new coronavirus drugs to AD drugs, it is shown that Simcere Pharmaceutical has gradually explored a set of suitable commercialization paths from independent research and development and cooperative research and development, and further promoted the pace
of drug research and development and commercialization of Simcere Pharmaceuticals.

epilogue

Conclusion Conclusion

With the increasing policy pressure of collection and medical insurance negotiation, how to meet the unmet clinical needs with high-quality and high-priced innovative drugs has become a problem
that traditional domestic pharmaceutical companies need to think about.

With the increasing policy pressure of collection and medical insurance negotiation, how to meet the unmet clinical needs with high-quality and high-priced innovative drugs has become a problem
that traditional domestic pharmaceutical companies need to think about.

Since its establishment in 1995, Simcere Pharmaceutical has experienced landing on the New York Stock Exchange, privatization, and then going to Hong Kong stock market, and the 27-year-old Simcere Pharmaceutical is actively investing in innovation and transformation
.

Since its establishment in 1995, Simcere Pharmaceutical has experienced landing on the New York Stock Exchange, privatization, and then going to Hong Kong stock market, and the 27-year-old Simcere Pharmaceutical is actively investing in innovation and transformation
.

Judging from the development of the past two years, Simcere Pharmaceutical has got rid of the previous "haze" and regrouped and started
again.

Judging from the development of the past two years, Simcere Pharmaceutical has got rid of the previous "haze" and regrouped and started
again.

"Focusing on being more effective and adhering to differentiation are the key words
for the innovation and transformation of Simcere Pharmaceuticals.
" Ren Jinsheng said
in the annual report.

"Focusing on being more effective and adhering to differentiation are the key words
for the innovation and transformation of Simcere Pharmaceuticals.
" Ren Jinsheng said
in the annual report.

Can Simcere Pharmaceuticals "take the lead" again? Worth looking forward to
.

Can Simcere Pharmaceuticals "take the lead" again? Worth looking forward to
.